COLLEGIUM PHARMACEUTICAL INC (COLL) Fundamental Analysis & Valuation

NASDAQ:COLL • US19459J1043

Current stock price

33.43 USD
+0.67 (+2.05%)
At close:
33.43 USD
0 (0%)
After Hours:

This COLL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. COLL Profitability Analysis

1.1 Basic Checks

  • In the past year COLL was profitable.
  • COLL had a positive operating cash flow in the past year.
  • COLL had positive earnings in 4 of the past 5 years.
  • COLL had a positive operating cash flow in each of the past 5 years.
COLL Yearly Net Income VS EBIT VS OCF VS FCFCOLL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • COLL's Return On Assets of 3.79% is amongst the best of the industry. COLL outperforms 84.38% of its industry peers.
  • COLL has a Return On Equity of 20.84%. This is amongst the best in the industry. COLL outperforms 91.15% of its industry peers.
  • COLL's Return On Invested Capital of 10.19% is amongst the best of the industry. COLL outperforms 89.06% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for COLL is in line with the industry average of 13.06%.
Industry RankSector Rank
ROA 3.79%
ROE 20.84%
ROIC 10.19%
ROA(3y)4.06%
ROA(5y)4.07%
ROE(3y)25.24%
ROE(5y)19.62%
ROIC(3y)12.68%
ROIC(5y)9.74%
COLL Yearly ROA, ROE, ROICCOLL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60

1.3 Margins

  • With an excellent Profit Margin value of 8.05%, COLL belongs to the best of the industry, outperforming 83.85% of the companies in the same industry.
  • In the last couple of years the Profit Margin of COLL has remained more or less at the same level.
  • COLL has a Operating Margin of 23.01%. This is amongst the best in the industry. COLL outperforms 89.58% of its industry peers.
  • In the last couple of years the Operating Margin of COLL has grown nicely.
  • With a decent Gross Margin value of 59.35%, COLL is doing good in the industry, outperforming 69.27% of the companies in the same industry.
  • COLL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 23.01%
PM (TTM) 8.05%
GM 59.35%
OM growth 3Y15.44%
OM growth 5Y4.89%
PM growth 3YN/A
PM growth 5Y-1.41%
GM growth 3Y8.71%
GM growth 5Y0.46%
COLL Yearly Profit, Operating, Gross MarginsCOLL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. COLL Health Analysis

2.1 Basic Checks

  • COLL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • COLL has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, COLL has less shares outstanding
  • The debt/assets ratio for COLL has been reduced compared to a year ago.
COLL Yearly Shares OutstandingCOLL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
COLL Yearly Total Debt VS Total AssetsCOLL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 1.39, we must say that COLL is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of COLL (1.39) is comparable to the rest of the industry.
  • The Debt to FCF ratio of COLL is 2.47, which is a good value as it means it would take COLL, 2.47 years of fcf income to pay off all of its debts.
  • COLL has a better Debt to FCF ratio (2.47) than 92.71% of its industry peers.
  • A Debt/Equity ratio of 2.59 is on the high side and indicates that COLL has dependencies on debt financing.
  • COLL has a Debt to Equity ratio of 2.59. This is amonst the worse of the industry: COLL underperforms 80.73% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for COLL, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 2.59
Debt/FCF 2.47
Altman-Z 1.39
ROIC/WACC1.11
WACC9.18%
COLL Yearly LT Debt VS Equity VS FCFCOLL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M

2.3 Liquidity

  • A Current Ratio of 1.57 indicates that COLL should not have too much problems paying its short term obligations.
  • COLL's Current ratio of 1.57 is on the low side compared to the rest of the industry. COLL is outperformed by 71.35% of its industry peers.
  • COLL has a Quick Ratio of 1.48. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
  • COLL has a Quick ratio of 1.48. This is in the lower half of the industry: COLL underperforms 66.15% of its industry peers.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.48
COLL Yearly Current Assets VS Current LiabilitesCOLL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. COLL Growth Analysis

3.1 Past

  • COLL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.66%, which is quite good.
  • The Earnings Per Share has been growing by 57.90% on average over the past years. This is a very strong growth
  • Looking at the last year, COLL shows a very strong growth in Revenue. The Revenue has grown by 23.62%.
  • Measured over the past years, COLL shows a very strong growth in Revenue. The Revenue has been growing by 20.28% on average per year.
EPS 1Y (TTM)15.66%
EPS 3Y137.06%
EPS 5Y57.9%
EPS Q2Q%15.25%
Revenue 1Y (TTM)23.62%
Revenue growth 3Y18.94%
Revenue growth 5Y20.28%
Sales Q2Q%12.92%

3.2 Future

  • COLL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.39% yearly.
  • COLL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.28% yearly.
EPS Next Y2.08%
EPS Next 2Y-5.87%
EPS Next 3Y-12.23%
EPS Next 5Y-2.39%
Revenue Next Year5.8%
Revenue Next 2Y0.34%
Revenue Next 3Y-0.21%
Revenue Next 5Y1.28%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
COLL Yearly Revenue VS EstimatesCOLL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
COLL Yearly EPS VS EstimatesCOLL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. COLL Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 4.48, the valuation of COLL can be described as very cheap.
  • Based on the Price/Earnings ratio, COLL is valued cheaper than 96.35% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.91. COLL is valued rather cheaply when compared to this.
  • COLL is valuated cheaply with a Price/Forward Earnings ratio of 4.39.
  • 95.83% of the companies in the same industry are more expensive than COLL, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.69, COLL is valued rather cheaply.
Industry RankSector Rank
PE 4.48
Fwd PE 4.39
COLL Price Earnings VS Forward Price EarningsCOLL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 98.96% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, COLL is valued cheaply inside the industry as 98.44% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 3.24
EV/EBITDA 3.22
COLL Per share dataCOLL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of COLL may justify a higher PE ratio.
  • A cheap valuation may be justified as COLL's earnings are expected to decrease with -12.23% in the coming years.
PEG (NY)2.15
PEG (5Y)0.08
EPS Next 2Y-5.87%
EPS Next 3Y-12.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. COLL Dividend Analysis

5.1 Amount

  • COLL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

COLL Fundamentals: All Metrics, Ratios and Statistics

COLLEGIUM PHARMACEUTICAL INC

NASDAQ:COLL (4/8/2026, 8:24:48 PM)

After market: 33.43 0 (0%)

33.43

+0.67 (+2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners122.15%
Inst Owner Change0%
Ins Owners2%
Ins Owner Change1.19%
Market Cap1.06B
Revenue(TTM)780.57M
Net Income(TTM)62.87M
Analysts81.67
Price Target55.25 (65.27%)
Short Float %13.78%
Short Ratio8.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.08%
Min EPS beat(2)-14.08%
Max EPS beat(2)7.92%
EPS beat(4)3
Avg EPS beat(4)-0.58%
Min EPS beat(4)-14.08%
Max EPS beat(4)7.92%
EPS beat(8)6
Avg EPS beat(8)8.51%
EPS beat(12)9
Avg EPS beat(12)-12.74%
EPS beat(16)10
Avg EPS beat(16)-13.58%
Revenue beat(2)1
Avg Revenue beat(2)3.07%
Min Revenue beat(2)-2.39%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.34%
Min Revenue beat(4)-2.39%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.58%
Revenue beat(12)5
Avg Revenue beat(12)-0.05%
Revenue beat(16)8
Avg Revenue beat(16)0.3%
PT rev (1m)0.93%
PT rev (3m)11.3%
EPS NQ rev (1m)-1.61%
EPS NQ rev (3m)-3.31%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.83%
Revenue NQ rev (1m)-0.95%
Revenue NQ rev (3m)-3.4%
Revenue NY rev (1m)1.83%
Revenue NY rev (3m)1.93%
Valuation
Industry RankSector Rank
PE 4.48
Fwd PE 4.39
P/S 1.36
P/FCF 3.24
P/OCF 3.22
P/B 3.52
P/tB N/A
EV/EBITDA 3.22
EPS(TTM)7.46
EY22.32%
EPS(NY)7.62
Fwd EY22.78%
FCF(TTM)10.32
FCFY30.86%
OCF(TTM)10.37
OCFY31.03%
SpS24.58
BVpS9.5
TBVpS-16.18
PEG (NY)2.15
PEG (5Y)0.08
Graham Number39.94
Profitability
Industry RankSector Rank
ROA 3.79%
ROE 20.84%
ROCE 14.76%
ROIC 10.19%
ROICexc 14.94%
ROICexgc 844.11%
OM 23.01%
PM (TTM) 8.05%
GM 59.35%
FCFM 41.97%
ROA(3y)4.06%
ROA(5y)4.07%
ROE(3y)25.24%
ROE(5y)19.62%
ROIC(3y)12.68%
ROIC(5y)9.74%
ROICexc(3y)19.7%
ROICexc(5y)15.04%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)18.36%
ROCE(5y)14.11%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y20.9%
ROICexc growth 5Y-2.38%
OM growth 3Y15.44%
OM growth 5Y4.89%
PM growth 3YN/A
PM growth 5Y-1.41%
GM growth 3Y8.71%
GM growth 5Y0.46%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.59
Debt/FCF 2.47
Debt/EBITDA 1.92
Cap/Depr 0.77%
Cap/Sales 0.22%
Interest Coverage 2.61
Cash Conversion 81.17%
Profit Quality 521.05%
Current Ratio 1.57
Quick Ratio 1.48
Altman-Z 1.39
F-Score7
WACC9.18%
ROIC/WACC1.11
Cap/Depr(3y)0.69%
Cap/Depr(5y)86.46%
Cap/Sales(3y)0.19%
Cap/Sales(5y)24.98%
Profit Quality(3y)461.5%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.66%
EPS 3Y137.06%
EPS 5Y57.9%
EPS Q2Q%15.25%
EPS Next Y2.08%
EPS Next 2Y-5.87%
EPS Next 3Y-12.23%
EPS Next 5Y-2.39%
Revenue 1Y (TTM)23.62%
Revenue growth 3Y18.94%
Revenue growth 5Y20.28%
Sales Q2Q%12.92%
Revenue Next Year5.8%
Revenue Next 2Y0.34%
Revenue Next 3Y-0.21%
Revenue Next 5Y1.28%
EBIT growth 1Y5.73%
EBIT growth 3Y37.3%
EBIT growth 5Y26.16%
EBIT Next Year47.71%
EBIT Next 3Y9.31%
EBIT Next 5Y7.76%
FCF growth 1Y61.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.66%
OCF growth 3Y38.41%
OCF growth 5Y28.53%

COLLEGIUM PHARMACEUTICAL INC / COLL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?

ChartMill assigns a fundamental rating of 6 / 10 to COLL.


What is the valuation status for COLL stock?

ChartMill assigns a valuation rating of 8 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.


How profitable is COLLEGIUM PHARMACEUTICAL INC (COLL) stock?

COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 8 / 10.


Can you provide the financial health for COLL stock?

The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.


What is the earnings growth outlook for COLLEGIUM PHARMACEUTICAL INC?

The Earnings per Share (EPS) of COLLEGIUM PHARMACEUTICAL INC (COLL) is expected to grow by 2.08% in the next year.